---
created: 2025-04-13
updated: 2025-04-13T10:52
id: tc!3`5xxV;
specialty: endo
specialty_id: 59
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/b&b::08-endocrinology::03-pancreas::04-treatment-of-diabetes
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::03-toxicities-&-side-effects::13-sulfa-drugs
  - "source/ak-step1-v11:": 
  - theme/firstaid::05-pharmacology::04-misc::01-drug-names
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy
  - "source/ak-step1-v11:": 
  - theme/firstaid::08-endocrine::05-pharm::01-diabetes-mellitus-therapy::sulfonylureas
  - "source/ak-step1-v11:": 
  - theme/ome::14-endocrine::05-pancreas::03-diabetes-pharm
  - "source/ak-step1-v11:": 
  - source/ome-banner::clinical::07-endocrinology::06-outpatient-diabetes
  - "source/ak-step1-v11:": 
  - theme/physeo::09-pharm::07-endocrine::04-sulfonylureas-and-meglitinides
  - "source/ak-step1-v11:": 
  - theme/pixorize::02-biochem::23-diabetes-drugs::06-second-gen-sylfonylureas
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::07-diabetes::second-gen-sulfonylureas
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::05-gi-&-endocrine::02-diabetes::01-insulin,-sulfonylureas,-meglitinides,-glp-1-agonists,-dpp-4-inhibitors
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::1000-1999::1655
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::11000-11999::11565
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::15000-15999::15881
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield
  - source/ak-step1-v11::^systems::endocrine::pharmacology
  - source/ak-step2-v11::!shelf::fm
  - source/ak-step2-v11::!shelf::fm::no-dupes
  - source/ak-step2-v11::!shelf::im
  - source/ak-step2-v11::!shelf::im::no-dupes
  - "source/ak-step2-v11:": 
  - theme/ome::07-endocrinology::05-outpatient-diabetes
  - "source/ak-step2-v11:": 
  - source/ome-banner
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::fm::ome::endo::outpatient-dm
  - "source/ak-step2-v11:": 
  - theme/resources-by-rotation::im::ome::endo::outpatient-dm
  - "source/ak-step2-v11:": 
  - theme/subjects::endocrinology::06-pancreas::diabetes::*management-redo
  - source/ak-step2-v11::original-decks::dorian::fam::ome::endo::outpatient-dm
  - source/ak-step2-v11::original-decks::dorian::im::ome::endo::outpatient-dm"
type: flashcard
---

# Question
What drug class do glyburide, glimepiride, and glipizide belong to?    **2nd gen. sulfonylureas::stimulate endogenous pancreatic insulin secretion independent of blood glucose lvls**   * Bonus: What marker can determine their use and why?

---

# Answer
glucose-INDEPENDENT endogenous insulin secretion == high risk of hypoglycemia   may be given in smaller doses x 1st gen sulfonylureas, therefore less risk of hypoglycemia